{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=28",
    "query": {
      "intervention": "Single intravenous doses of placebo",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 677,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T15:12:49.842Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01258907",
      "title": "A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "MLDL1278A",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "statin, stable dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 147,
      "start_date": "2010-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 22,
      "location_summary": "Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01258907"
    },
    {
      "nct_id": "NCT02586233",
      "title": "Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke",
        "Thrombotic Disease"
      ],
      "interventions": [
        {
          "name": "DS-1040b",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2015-09",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 16,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02586233"
    },
    {
      "nct_id": "NCT04027387",
      "title": "Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "TMB-365",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-12-14",
      "completion_date": "2021-08-18",
      "has_results": false,
      "last_update_posted_date": "2021-10-06",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04027387"
    },
    {
      "nct_id": "NCT02925416",
      "title": "Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Diseases, Bacterial"
      ],
      "interventions": [
        {
          "name": "Oritavancin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (D5W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-01-24",
      "completion_date": "2017-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 1,
      "location_summary": "Somers Point, New Jersey",
      "locations": [
        {
          "city": "Somers Point",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925416"
    },
    {
      "nct_id": "NCT00489424",
      "title": "Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Fluvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "79 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 79 Years · Female only"
      },
      "enrollment_count": 793,
      "start_date": "2007-06",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2011-02-18",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 1,
      "location_summary": "Http://www.osteoporosisclinicalresearch.com, New Jersey",
      "locations": [
        {
          "city": "Http://www.osteoporosisclinicalresearch.com",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489424"
    },
    {
      "nct_id": "NCT01375985",
      "title": "Safety Study of Single Administration Intravenous Treatment for Influenza",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "AVI-7100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 8,
      "start_date": "2011-06",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-11",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375985"
    },
    {
      "nct_id": "NCT04618263",
      "title": "Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Excessive Sleepiness"
      ],
      "interventions": [
        {
          "name": "GATE-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndeio Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-10-26",
      "completion_date": "2021-08-13",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 1,
      "location_summary": "Eatontown, New Jersey",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04618263"
    },
    {
      "nct_id": "NCT02341508",
      "title": "A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "0.5 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline solution for intravenous infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-09",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-06",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341508"
    },
    {
      "nct_id": "NCT05872958",
      "title": "Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AZD3152",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-19",
      "completion_date": "2024-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 4,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05872958"
    },
    {
      "nct_id": "NCT00048568",
      "title": "A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1250,
      "start_date": "2002-12",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-10-19T15:12:49.842Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048568"
    }
  ]
}